| Popis: |
The mortality rate for the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic is increasing worldwide with each passing day. The risk factors for mortality include advanced age and comorbidities. It is still uncertain whether biological agents pose a risk for the progression of SARS-CoV-2. Although there are studies suggesting the use of biological agents in the literature, there are also studies suggesting the discontinuation of biological agents during SARS-CoV-2. In this study, we aimed to determine whether anti-tumor necrosis factor (anti-TNF-alpha agents) therapy, which is one of the biological agents commonly used in rheumatology clinics, has an effect on the clinical course of SARS-CoV-2 infection, and to review the literature. We searched the MEDLINE/PubMed and SCOPUS databases until the date of August 15, 2020, using the following keywords: SARS-CoV-2 and anti-TNF-alpha agents. We reviewed abstracts and retrieved the relevant articles. We reported the clinical manifestation and disease course of SARS-CoV-2 pneumonia in three patients with ankylosing spondylitis who were receiving anti-TNF-alpha agents. All patients in our case series had a mild course similar to the most cases reported in the literature. C1 [Kaymaz, Serdar; Karasu, Ugur; Cobankara, Veli; Ulutas, Firdevs] Pamukkale Univ, Fac Med, Dept Rheumatol, TR-20070 Denizli, Turkey. [Alkan, Hakan] Pamukkale Univ, Fac Med, Dept Phys Med & Rehabil, Denizli, Turkey. |
